Dyadic's C1 Platform Validated by Gates Foundation Grant, Rapid Production Milestones
DYAI sits 47% above its 52-week low of $0.655 on light trading volume (0.2× avg).
Summary
Dyadic International announced significant progress in its global collaborations, validating its C1 protein production platform. The company received the full $3.1 million Gates Foundation grant, with the final $738,743 payment in June 2026, for its RSV and malaria monoclonal antibody programs. Studies show C1-produced antibodies are comparable to traditional systems but with higher yields and lower costs. Additionally, the C1 platform demonstrated plasmid-to-purified-protein production in approximately 15 days in a CEPI/FBS collaboration. This positive operational news provides a counterpoint to the company's recent Nasdaq delisting notice and negative shareholder equity, highlighting the potential of its core technology. Initial purified antigen samples for the Scripps Ebola collaboration are expected by the end of July 2026.
At the time of this announcement, DYAI was trading at $0.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $35.3M. The 52-week trading range was $0.65 to $1.35. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.